---
sidebar_position: 44
---

# 文獻 44：Redefining ALS: Large-scale proteomic profiling reveals a prolonged pre-diagnostic phase with immune muscular metabolic and brain involvement

**English Title**: Redefining ALS: Large-scale proteomic profiling reveals a prolonged pre-diagnostic phase with immune muscular metabolic and brain involvement

**中文標題**: 重新定義 ALS：大規模蛋白質組學分析揭示涉及免疫、肌肉、代謝和大腦的延長診斷前期
**PMID**: 40909834
**期刊**: medRxiv
**評分**: 7
**應用領域**: 未明確
**DOI**: https://doi.org/10.1101/2025.08.20.25334061

---

## 📌 第一張：核心觀點卡

### 主要發現
診斷前期多系統參與發現

### 文獻摘要（Abstract）
BACKGROUND: Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disorder with a largely unknown duration and pathophysiology of the pre-diagnostic phase, especially for the common non-monogenic form. METHODS: We leveraged the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort with up to 30 years of follow-up to identify incident ALS cases across five European countries. Pre-diagnostic plasma samples from initially healthy participants underwent high-throughput proteomic profiling (7,285 protein markers, SomaScan). Cox proportional hazards models based on 4,567 participants (including 172 incident ALS cases) were used to identify protein biomarkers associated with future ALS diagnosis. Top results were indirectly validated in two independent case-control studies of prevalent ALS (n=417 ALS, 852 controls). Functional annotation included cross-disease comparisons, gene set and tissue enrichment testing, organ-specific proteomic clocks, and the application of large-language models (LLM). FINDINGS: Five proteins (SECTM1, CA3, THAP4, KLHL41, SLC26A7) were identified as significant pre-diagnostic ALS biomarkers (FDR=0.05), detectable approximately two decades before diagnosis. Of these, all except SECTM1 were indirectly validated in independent cohorts of prevalent ALS cases, supporting their clinical significance. Additionally, 22 nominally significant (p&lt;0.05) pre-diagnostic biomarkers were FDR-significant in prevalent ALS with consistent effect directions. Cross-disease comparisons with pre-diagnostic Parkinson's and Alzheimer's disease suggested a largely specific pre-diagnostic ALS biomarker signature. Gene ontology and tissue enrichment highlighted early involvement of immune, muscle, metabolic, and digestive processes. Furthermore, analyses of proteomic clocks revealed accelerated aging in brain-cognition, immune, and muscle tissues before clinical diagnosis. Druggability and LLM analyses revealed possible therapeutic targets and novel strategies, emphasizing translational relevance. INTERPRETATION: Our study provides first evidence of ultra-early molecular changes in common ALS up to two decades prior to clinical onset, mainly affecting immune, muscle, metabolic, digestive, and cognitive systems. Our study nominates several compelling candidates for risk stratification studies and novel therapeutic targets for early intervention. FUNDING: Clinical Research in ALS and Related Disorders for Therapeutic Development (CreATe) Consortium, Cure Alzheimer's Fund, Michael J Fox Foundation, Interdisciplinary Centre for Clinical Research, University Münster.

### 關鍵數據
- **研究類型**: 未分類
- **國家/地區**: 待查
- **發表年份**: 待查
- **ROI 數值**: 無數值

### 核心創新點
本研究的主要創新在於：診斷前期多系統參與發現

---

## ✍️ 第二張：Paraphrase 卡

### 研究目的與方法
本研究聚焦於未明確領域，旨在探討 AI 技術在醫療場景中的應用。

### 主要貢獻
研究提出了診斷前期多系統參與發現，為臨床實踐提供了新的解決方案。

### 技術特點
- 應用場景：未明確
- 創新程度：評分 7/10
- 期刊影響：發表於 medRxiv

---

## ❓ 第三張：問答卡

### Q1: 這項研究解決了什麼問題？
A: 本研究針對未明確領域的挑戰，提出了基於 AI 的解決方案。

### Q2: 採用了什麼技術方法？
A: 診斷前期多系統參與發現

### Q3: 研究的主要成果是什麼？
A: 研究獲得了 7 分的專家評分，證明了其在未明確領域的應用價值。

### Q4: 有哪些實際應用場景？
A: 主要應用於未明確，可用於改善醫療服務品質和效率。

---

## 🤔 第四張：例外卡

### 潛在限制
1. **研究範圍**: 研究評分為 7/10，可能存在改進空間
2. **地區差異**: 研究來自待查，其他地區適用性需驗證
3. **ROI 數據**: 無數值，經濟效益評估可能不完整

### 需要進一步探討的問題
1. 該技術在不同規模醫院的適用性如何？
2. 長期使用的效果和穩定性是否經過驗證？
3. 與現有系統整合時可能面臨哪些挑戰？

### 批判性思考
- **技術成熟度**: 需要評估從研究到實際部署的距離
- **成本效益**: 無數值，需要更詳細的經濟分析
- **倫理考量**: AI 在未明確應用時的倫理和隱私問題
- **可推廣性**: 研究結果在其他醫療場景的適用性

---

## 📚 參考資訊
- **PMID**: [40909834](https://pubmed.ncbi.nlm.nih.gov/40909834/)
- **DOI**: https://doi.org/10.1101/2025.08.20.25334061
- **期刊**: medRxiv
